1
|
Coutre SE, Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, Hillmen P, Devereux S, Grosicki S, McCarthy H, Li J, Simpson D, Offner F, Moreno C, Dai S, Szoke A, Dean JP, Kipps TJ, Ghia P. FIRST‐LINE TREATMENT WITH IBRUTINIB FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): 7‐YEAR RESULTS FROM RESONATE‐2. Hematol Oncol 2021. [DOI: 10.1002/hon.48_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- S. E. Coutre
- Stanford Cancer Center, Stanford University School of Medicine, Stanford California USA
| | - P. M. Barr
- Wilmot Cancer Institute, University of Rochester Medical Center, Clinical Trials Office Rochester USA
| | - C. Owen
- Tom Baker Cancer Centre, University of Calgary, Medicine and Oncology Calgary Canada
| | - T. Robak
- Medical University of Lodz, Copernicus Memorial Hospital, Hematology Lodz Poland
| | - A. Tedeschi
- ASST Grande Ospedale Metropolitano Niguarda, Hematology Milan Italy
| | - O. Bairey
- Rabin Medical Center, Life and Medicine Sciences Petah Tikva Israel
| | - J. A. Burger
- University of Texas MD Anderson Cancer Center, Leukemia Houston USA
| | - P. Hillmen
- The Leeds Teaching Hospitals, St. James Institute of Oncology, Oncology Leeds UK
| | - S. Devereux
- Kings College Hospital, NHS Foundation Trust, Lymphoma Biology London UK
| | - S. Grosicki
- School of Public Health, Silesian Medical University, Hematology and Cancer Prevention Katowice Poland
| | - H. McCarthy
- Royal Bournemouth General Hospital, Hematology Bournemouth UK
| | - J. Li
- Jiangsu Province Hospital, Hematology Nanjing China
| | - D. Simpson
- North Shore Hospital, Hematology Auckland New Zealand
| | - F. Offner
- Universitair Ziekenhuis Gent, Internal Medicine and Pediatrics Gent Belgium
| | - C. Moreno
- Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Hematology Barcelona Spain
| | - S. Dai
- Pharmacyclics LLC, an AbbVie Company, Biostatistics Sunnyvale USA
| | - A. Szoke
- Pharmacyclics LLC, an AbbVie Company, Oncology Sunnyvale USA
| | - J. P. Dean
- Pharmacyclics LLC, an AbbVie Company, Oncology Sunnyvale USA
| | - T. J. Kipps
- UCSD Moores Cancer Center, Blood Cancer Research Fund San Diego USA
| | - P. Ghia
- Università Vita‐Salute San Raffaele and IRCCS Ospedale San Raffaele, Medical Oncology Milan Italy
| |
Collapse
|
2
|
Tedeschi A, Burger J, Barr P, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Coutre S, Devereux S, Grosicki S, McCarthy H, Li J, Simpson D, Offner F, Moreno C, Dai S, Lal I, Dean J, Kipps T. FIVE-YEAR FOLLOW-UP OF FIRST-LINE IBRUTINIB FOR TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA//SMALL LYMPHOCYTIC LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.67_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- A. Tedeschi
- Department of Hematology; ASST Grande Ospedale Metropolitano Niguarda; Milan Italy
| | - J. Burger
- Department of Leukemia; University of Texas MD Anderson Cancer Center; Houston TX United States
| | - P.M. Barr
- Department of Medicine, Wilmot Cancer Institute; University of Rochester Medical Center; Rochester NY United States
| | - T. Robak
- Department of Hematology, Medical University of Lodz; Copernicus Memorial Hospital; Lodz Poland
| | - C. Owen
- Department of Oncology; Tom Baker Cancer Centre, University of Calgary; Calgary AB Canada
| | - P. Ghia
- Department of Experimental Oncology; Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele; Milan Italy
| | - O. Bairey
- Department of Hematology; Rabin Medical Center; Petah Tikva Israel
| | - P. Hillmen
- Department of Medicine, The Leeds Teaching Hospitals; St. James Institute of Oncology; Leeds United Kingdom
| | - S. Coutre
- Department of Medicine, Stanford Cancer Center; Stanford University School of Medicine; Stanford CA United States
| | - S. Devereux
- Department of Hematology; Kings College Hospital, NHS Foundation Trust; London United Kingdom
| | - S. Grosicki
- Department of Internal Medicine; School of Public Health, Silesian Medical University; Katowice Poland
| | - H. McCarthy
- Department of Hematology; Royal Bournemouth General Hospital; Bournemouth United Kingdom
| | - J. Li
- Department of Medicine; Jiangsu Province Hospital; Nanjing China
| | - D. Simpson
- Department of Hematology; North Shore Hospital; Auckland New Zealand
| | - F. Offner
- Department of Clinical Hematology; Universitair Ziekenhuis Gent; Gent Belgium
| | - C. Moreno
- Department of Hematology; Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona; Barcelona Spain
| | - S. Dai
- Department of Biostatistics; Pharmacyclics LLC, an AbbVie Company; Sunnyvale CA United States
| | - I. Lal
- Department of Clinical Science; Pharmacyclics LLC, an AbbVie Company; Sunnyvale CA United States
| | - J.P. Dean
- Department of Clinical Science; Pharmacyclics LLC, an AbbVie Company; Sunnyvale CA United States
| | - T.J. Kipps
- Department of Medicine; UCSD Moores Cancer Center; La Jolla CA United States
| |
Collapse
|
3
|
Lammer F, May L, Martus P, Schroers R, Schlegel U, Hofer S, Bairey O, Schmitz N, Griesinger F, Schmidt-Hieber M, Weißinger F, Reimer P, le Coutre P, Fix P, Hopfer O, Junghanß C, Höffkes H, Heilmeier B, Möhle R, Lange E, Korfel A, Keller U. PROSPECTIVE MULTICENTER REGISTRY FOR SECONDARY CNS INVOLVEMENT IN MALIGNANT LYMPHOMA: AN UPDATE WITH DATA FROM 181 PATIENTS. Hematol Oncol 2019. [DOI: 10.1002/hon.64_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- F. Lammer
- Haematology; Oncology, Charité University Medicine; Berlin Germany
| | - L. May
- Haematology; Oncology, Charité University Medicine; Berlin Germany
| | - P. Martus
- Institute of Clinical Epidemiology and Applied Biostatistics; University Hospital Tübingen; Tübingen Germany
| | - R. Schroers
- Haematology; Oncology, Knappschaftskrankenhaus, Ruhr-Universität Bochum; Bochum Germany
| | - U. Schlegel
- Neurology; Knappschaftskrankenhaus, Ruhr-Universität Bochum; Bochum Germany
| | - S. Hofer
- Oncology; Luzerner Kantonsspital; Luzern Switzerland
| | - O. Bairey
- Haematology; Tel Aviv University; Tel Aviv Israel
| | - N. Schmitz
- Haematology; Oncology, Universitätsklinikum Münster; Münster Germany
| | - F. Griesinger
- Haematology; Oncology, Pius Hospital Oldenburg; Oldenburg Germany
| | | | - F. Weißinger
- Haematology; Oncology, Evangelisches Klinikum Bethel; Bielefeld Germany
| | - P. Reimer
- Haematology; Oncology, St. Josef Krankenhaus Essen-Werden; Essen Germany
| | - P. le Coutre
- Haematology; Oncology, Charité University Medicine; Berlin Germany
| | - P. Fix
- Haematology; Oncology, Klinikum Weimar; Weimar Germany
| | - O. Hopfer
- Haematology; Oncology, Klinikum Frankfurt (Oder); Frankfurt (Oder) Germany
| | - C. Junghanß
- Haematology; Oncology, University Rostock; Rostock Germany
| | - H. Höffkes
- Haematology; Oncology, Klinikum Fulda; Fulda Germany
| | - B. Heilmeier
- Oncology; Krankenhaus Barmherzige Brüder; Regensburg Germany
| | - R. Möhle
- Haematology; Oncology, University Hospital Tübingen; Tübingen Germany
| | - E. Lange
- Haematology; Oncology, Evangelisches Krankenhaus Hamm; Hamm Germany
| | - A. Korfel
- Haematology; Oncology, Charité University Medicine; Berlin Germany
| | - U. Keller
- Haematology; Oncology, Charité University Medicine; Berlin Germany
| |
Collapse
|
4
|
Korfel A, Schroers R, Schlegel U, Schmitz N, Hofer S, Bairey O, Schmidt-Hieber M, Le Coutre P, Janz M, Reimer P, Martus P. CURRENT THERAPY OF SECONDARY CNS INVOLVEMENT IN MALIGNANT LYMPHOMA: DATA FROM A MULTICENTER PROSPECTIVE INTERNATIONAL REGISTRY. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_58] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- A. Korfel
- Hematology and Oncology; Charite University Medicine Berlin; Berlin Germany
| | - R. Schroers
- Hematology and Oncology; Knappschaftskrankenhaus, Ruhr-Universität Bochum; Bochum Germany
| | - U. Schlegel
- Neurology; Knappschaftskrankenhaus, Ruhr-Universität Bochum; Bochum Germany
| | - N. Schmitz
- Hematology and Oncology; Asklepios Klinik Skt. Georg; Hamburg Germany
| | - S. Hofer
- Oncology; Kantonsspital Luzern; Luzern Switzerland
| | - O. Bairey
- Sackler School of Medicine; Tel Aviv University; Tel Aviv Israel
| | - M. Schmidt-Hieber
- Hematology and Oncology; HELIOS Klinikum Berlin-Buch; Berlin Germany
| | - P. Le Coutre
- Hematology and Oncology; Charite University Medicine Berlin; Berlin Germany
| | - M. Janz
- Hematology and Oncology; Charite University Medicine Berlin; Berlin Germany
| | - P. Reimer
- Hematology amd Oncology; Evangelisches Krankenhaus Essen-Werden; Essen Germany
| | - P. Martus
- Clinical Epidemiology and Biometry; University Tuebingen; Tübingen Germany
| |
Collapse
|
5
|
Korfel A, Schroers R, Schlegel U, Schmitz N, Hofer S, Bairey O, Schmidt-Hieber M, Hirsch A, Reimer P, Martus P. P14.10 Secondary CNS involvement in malignant lymphoma: Data from a multicenter prospective international registry. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox036.397] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
6
|
Kasenda B, Ferreri AJM, Marturano E, Forst D, Bromberg J, Ghesquieres H, Ferlay C, Blay JY, Hoang-Xuan K, Pulczynski EJ, Fosså A, Okoshi Y, Chiba S, Fritsch K, Omuro A, O'Neill BP, Bairey O, Schandelmaier S, Gloy V, Bhatnagar N, Haug S, Rahner S, Batchelor TT, Illerhaus G, Briel M. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis. Ann Oncol 2015; 26:1305-13. [PMID: 25701456 DOI: 10.1093/annonc/mdv076] [Citation(s) in RCA: 121] [Impact Index Per Article: 13.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2014] [Accepted: 02/10/2015] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND To investigate prognosis and effects of first-line therapy in elderly primary central nervous system lymphoma (PCNSL) patients. PATIENTS AND METHODS A systematic review of studies about first-line therapy in immunocompetent patients ≥60 years with PCNSL until 2014 and a meta-analysis of individual patient data from eligible studies and international collaborators were carried out. RESULTS We identified 20 eligible studies; from 13 studies, we obtained individual data of 405 patients, which were pooled with data of 378 additional patients (N = 783). Median age and Karnofsky Performance Score (KPS) was 68 years (range: 60-90 years) and 60% (range: 10%-100%), respectively. Treatments varied greatly, 573 (73%) patients received high-dose methotrexate (HD-MTX)-based therapy. A total of 276 patients received whole-brain radiotherapy (median 36 Gy, range 28.5-70 Gy). KPS ≥ 70% was the strongest prognostic factor for mortality [hazard ratio (HR) 0.50, 95% confidence interval (CI) 0.41-0.62]. After a median follow-up of 40 months, HD-MTX-based therapy was associated with improved survival (HR 0.70, 95% CI 0.53-0.93). There was no difference between HD-MTX plus oral chemotherapy and more aggressive HD-MTX-based therapies (HR 1.39, 95% CI 0.90-2.15). Radiotherapy was associated with an improved survival, but correlated with an increased risk for neurological side-effects (odds ratio 5.23, 95% CI 2.33-11.74). CONCLUSIONS Elderly PCNSL patients benefit from HD-MTX-based therapy, especially if combined with oral alkylating agents. More aggressive HD-MTX protocols do not seem to improve outcome. WBRT may improve outcome, but is associated with increased risk for neurological side-effects. Prospective trials for elderly PCNSL patients are warranted.
Collapse
Affiliation(s)
- B Kasenda
- Department of Oncology, University Hospital of Basel, Basel Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland
| | - A J M Ferreri
- Unit of Lymphoid Malignancies, Department of Onco-Hematology, San Raffaele Scientific Institute, Milan, Italy
| | - E Marturano
- Unit of Lymphoid Malignancies, Department of Onco-Hematology, San Raffaele Scientific Institute, Milan, Italy
| | - D Forst
- Partners Neurology Residency Program, Harvard Medical School, Boston, USA
| | - J Bromberg
- Department of Neuro-Oncology, Daniel den Hoed Cancer Center, Erasmus MC University Medical Center, Rotterdam, The Netherlands
| | - H Ghesquieres
- Department of Hematology, Centre Léon Bérard, University of Lyon, Lyon
| | - C Ferlay
- Department of Hematology, Centre Léon Bérard, University of Lyon, Lyon
| | - J Y Blay
- Department of Hematology, Centre Léon Bérard, University of Lyon, Lyon
| | - K Hoang-Xuan
- Department of Neurology Mazarin, LOC National Expert Center, APHP, IHU, UPMC, CRICM, GH Pitié-Salpêtrière, Paris, France
| | - E J Pulczynski
- Department of Haematology, Nordic Lymphoma Group, University Hospital Aarhus, Aarhus, Denmark
| | - A Fosså
- Norwegian Department of Oncology, Nordic Lymphoma Group, Radium Hospital, Oslo, Norway
| | - Y Okoshi
- Faculty of Medicine, Department of Hematology, University of Tsukuba, Tsukuba, Japan
| | - S Chiba
- Faculty of Medicine, Department of Hematology, University of Tsukuba, Tsukuba, Japan
| | - K Fritsch
- Department of Hematology/Oncology, University Hospital Freiburg, Freiburg, Germany
| | - A Omuro
- Department of Neurology Mazarin, LOC National Expert Center, APHP, IHU, UPMC, CRICM, GH Pitié-Salpêtrière, Paris, France
| | - B P O'Neill
- Department of Neurology, Mayo Medical School, Rochester, USA
| | - O Bairey
- Institute of Hematology, Rabin Medical Center, Beilinson Hospital, Tel Aviv Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - S Schandelmaier
- Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland
| | - V Gloy
- Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland
| | - N Bhatnagar
- Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada
| | - S Haug
- Psychiatry and Psychotherapy, University Hospital Freiburg, Freiburg
| | - S Rahner
- Medical Faculty, University of Freiburg, Freiburg, Germany
| | - T T Batchelor
- Partners Neurology Residency Program, Harvard Medical School, Boston, USA Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital, Boston, USA
| | - G Illerhaus
- Stuttgart Cancer Center, Eva-Mayr-Stihl Tumor Center, Stuttgart, Germany
| | - M Briel
- Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada
| |
Collapse
|
7
|
Abstract
Chronic lymphocytic leukemia (CLL) cells are characterized by defective apoptosis which leads to their extended survival. Arsenic trioxide (As(2)O(3)) was reported to induce cell death in many malignant cells, but the specific pathway of As(2)O(3)-induced apoptosis/necrosis remains controversial. Our aim was to determine if As(2)O(3) kills CLL cells through apoptosis and whether this is accompanied by reduction in Bcl-2 levels. Cells from nine patients with CLL were incubated with increasing concentrations of As(2)O(3) (0.5-2 microM) for 2, 7, or 14 days. Cells viability was measured using Alamar Blue assay and apoptosis using human Annexin V-FITC and propidium iodine (PI) kit (BMS306FI; Bender MedSystems, Vienna, Austria). Intracellular Bcl-2, Bax, and caspase-3 levels were measured by flow cytometry. As(2)O(3) significantly reduced CLL cell viability (P < 0.01) and induced apoptotic cell death in a time- and dose-dependent manner. After 7 days, CLL cells showed a significant decrease in mean fluorescence intensity (MFI) of Bcl-2 on flow cytometry study. Bax and caspase-3 levels showed significant decrease in MFI only after prolonged incubations (7 and 14 days) and mostly at higher concentrations of As(2)O(3). The mechanism underlying the reduction in viability of CLL cells incubated with As(2)O(3) is mediated by induction of apoptosis maybe through the down-regulation of Bcl-2. Further studies are needed to elucidate the potential therapeutic role of As(2)O(3) in CLL.
Collapse
Affiliation(s)
- O Bairey
- Institute of Hematology, Rabin Medical Center, Beilinson Hospital, Petah Tiqwa, Israel.
| | | | | |
Collapse
|
8
|
Abstract
BACKGROUND Very elderly patients (> or =80 years old) with non-Hodgkin's lymphoma (NHL) frequently have co-morbid conditions and are generally excluded from clinical trials or even from treatment. The optimal treatment of these patients is unknown. PATIENTS AND METHODS We reviewed the records of 109 patients > or =80 years at diagnosis of NHL (65 F/44 M; median age: 84 years, range; 80-95). RESULTS Seventy-eight patients (72%) had aggressive NHL, 25 (23%) had indolent and NHL, eight had unclassified disease. Advanced-stage disease was noted in 54%. Forty patients (39%) had a poor ECOG performance status (PS), and 52 (49%) had an intermediate or high risk International Prognostic Index (IPI). Seventy-nine patients (72%) were treated with chemotherapy and 37 (34%) with radiotherapy. Initial chemotherapy consisted of chlorambucil in 15, oral etoposide in 2, and combination protocol in 62. Only 16% of patients received full-dose therapy, and only 50% completed > or =6 cycles of combination chemotherapy. The overall response rate for the 69 evaluable patients was 84% (complete 56.5%, partial 27.5%). Overall 5-year survival for the whole group was 39%, and median survival time was 26 months. CONCLUSION A high response rate can be achieved in very elderly NHL patients despite aggressive histology, poor prognostic features, and reduced doses of chemotherapy. Age alone should not be a contraindication to treatment.
Collapse
Affiliation(s)
- O Bairey
- Institute of Hematology, Rabin Medical Center, Beilinson Campus, Petah Tiqwa, Department of Internal Medicine A, Sapir Medical Center, Kfar Saba, Israel.
| | | | | | | | | |
Collapse
|
9
|
Bairey O, Shaklai M. Serum CA 125 levels in patients with chronic lymphocytic leukemia. Clin Lab Haematol 2005; 27:57-60. [PMID: 15686509 DOI: 10.1111/j.1365-2257.2004.00656.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/01/2023]
Abstract
Cancer antigen 125 (CA 125) is a glycoprotein expressed in normal tissues originally derived from celomic epithelia and its serum level is elevated in various benign and malignant conditions that involve stimulation of these tissues. Elevated levels have been reported in 40-43% of patients with non-Hodgkin's lymphoma (NHL) at diagnosis and were associated with parameters known to be associated with advanced and disseminated disease, and with event-free and overall survival. No difference in CA 125 level was found between indolent and aggressive lymphomas, and four of six patients with small lymphocytic lymphoma had elevated CA 125 levels. We therefore decided to measure serum CA 125 levels in chronic lymphocytic leukemia (CLL) patients, and evaluated them in 74 consecutive patients. The mean time from diagnosis to test was 74.5 months (range: 0-300). The mean serum CA 125 level was 16.3 U/ml (range: 3.7-133, normal value: <35 U/ml). CA 125 levels were elevated only in two patients (2.7%). To conclude, serum CA 125 levels are rarely elevated in CLL patients. It is possible that serum CA 125 levels can help differentiate between equivocal cases of small lymphocytic lymphoma and CLL.
Collapse
Affiliation(s)
- O Bairey
- Institute of Hematology and Felsenstein Medical Research Center, Rabin Medical Center, Beilinson Campus, Petah Tiqva and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
| | | |
Collapse
|
10
|
Bairey O, Boycov O, Kaganovsky E, Zimra Y, Shaklai M, Rabizadeh E. All three receptors for vascular endothelial growth factor (VEGF) are expressed on B-chronic lymphocytic leukemia (CLL) cells. Leuk Res 2004; 28:243-8. [PMID: 14687619 DOI: 10.1016/s0145-2126(03)00256-x] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
B-chronic lymphocytic leukemia (B-CLL) cells have a long survival owing to an alteration in the normal pathways of apoptosis. CLL cells have been found to produce and secrete vascular endothelial growth factor (VEGF). In addition to its major role in angiogenesis, VEGF affects cell survival by interfering with apoptosis. The aim of the present study was to investigate the expression of the VEGF receptors VEGFR-1, VEGFR-2, and VEGFR-3 on B-CLL cells, singly and combined. B-CLL cells were isolated from peripheral blood drawn from patients with CLL. Total VEGF receptor, examined in 13 samples by flow cytometry was present in all cases with mean CD19+/VEGF+ expression of 76% (range 52-92%). Specific receptor expression, examined in 27 samples by immunocytochemical methods, was positive for VEGFR-1 in all 27 patients and for VEGFR-2 and VEGFR-3 in 26 (96%). These findings suggest that the VEGF transduction pathway may be very active in CLL cells, and both its paracrine and autocrine pathways may contribute to their enhanced survival.
Collapse
Affiliation(s)
- O Bairey
- Institute of Hematology and the Felsenstein Medical Research Center, Rabin Medical Center, Beilinson Campus Petah Tikva 49100, Israel.
| | | | | | | | | | | |
Collapse
|
11
|
Pazgal I, Zimra Y, Tzabar C, Okon E, Rabizadeh E, Shaklai M, Bairey O. Expression of basic fibroblast growth factor is associated with poor outcome in non-Hodgkin's lymphoma. Br J Cancer 2002; 86:1770-5. [PMID: 12087465 PMCID: PMC2375415 DOI: 10.1038/sj.bjc.6600330] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2002] [Revised: 03/26/2002] [Accepted: 03/27/2002] [Indexed: 12/03/2022] Open
Abstract
It is now clear that angiogenesis and angiogenesis factors are important in the pathogenesis of haematological malignancies. High pretreatment levels of serum basic fibroblast growth factor have been shown to be associated with poor prognosis in patients with non-Hodgkin's lymphoma. The aim of this study was to evaluate whether non-Hodgkin's lymphoma cells express basic fibroblast growth factor and/or its receptor (fibroblast growth factor receptor-1) and whether basic fibroblast growth factor expression correlates with basic fibroblast growth factor serum levels, intratumoral microvessel density, and patient outcome. We measured basic fibroblast growth factor by enzyme-linked immunosorbent assay in sera taken from 58 patients with non-Hodgkin's lymphoma before treatment and in 19 of them also after treatment. Pathological specimens at diagnosis were evaluated by immunohistochemistry staining using polyoclonal antibody against factor-VIII-related antigen, basic fibroblast growth factor and fibroblast growth factor receptor-1 to determine the expression of the microvessel count and basic fibroblast growth factor and fibroblast growth factor receptor-1. The lymphoma specimens demonstrated positive staining for basic fibroblast growth factor (in 23%) and fibroblast growth factor receptor-1 (in 58.5%). The patients who expressed basic fibroblast growth factor had a significantly worse progression-free and overall survival than those who did not (P=0.003 and P=0.03 respectively), while patients expressing fibroblast growth factor receptor-1 were less likely to achieve complete remission than those lacking the receptor (33% vs 65%, P=0.047). There was no correlation of basic fibroblast growth factor staining with either serum basic fibroblast growth factor levels or microvessel count. Basic fibroblast growth factor serum levels did not change significantly after treatment These results suggest that non-Hodgkin's lymphoma specimens express basic fibroblast growth factor and its receptor (fibroblast growth factor receptor-1) and this expression is associated with poor patient outcome.
Collapse
Affiliation(s)
- I Pazgal
- Institute of Hematology and Felsenstein Medical Research Center, Rabin Medical Center, Beilinson Campus, Petah Tiqva, 49100, Israel
| | | | | | | | | | | | | |
Collapse
|
12
|
Shapira Y, Bairey O, Vatury M, Magen-Nativ H, Prokocimer M, Sagie A. Erythropoietin can obviate the need for repeated heart valve replacement in high-risk patients with severe mechanical hemolytic anemia: case reports and literature review. J Heart Valve Dis 2001; 10:431-5. [PMID: 11499585] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Abstract
BACKGROUND AND AIM OF THE STUDY Brisk hemolysis due to perivalvular leak is usually an indication for valve re-replacement. Repeated surgery after multiple previous valve operations is associated with high mortality, morbidity and failure rates. The present study evaluated the role of erythropoietin (EPO) administration in deferring or obviating the need for repeated surgery. METHODS Three patients (two men, one woman; age range 62-76 years) with two mechanical valves each and two to four previous heart valve operations, who suffered from severe mechanical hemolytic anemia, were given subcutaneous EPO for 15-17 months. RESULTS A marked reduction in red blood cell consumption was achieved with a weekly EPO dose of 18,000 U in two patients, both of whom also had mild or moderate kidney malfunction. A third patient with normal renal function and extreme hemolysis showed a transient, partial response to 30,000 U of EPO per week, and eventually needed a fifth operation. CONCLUSION EPO may defer or even obviate the need for repeated valve surgery in patients with severe hemolysis due to perivalvular leak, especially those with inadequate EPO response, such as those with renal malfunction.
Collapse
Affiliation(s)
- Y Shapira
- The Dan Sheingarten Echocardiography Unit and Valvular Clinic, Department of Cardiology, Rabin Medical Center, Petah Tiqva, Israel
| | | | | | | | | | | |
Collapse
|
13
|
Bairey O, Zimra Y, Shaklai M, Rabizadeh E. Bcl-2 expression correlates positively with serum basic fibroblast growth factor (bFGF) and negatively with cellular vascular endothelial growth factor (VEGF) in patients with chronic lymphocytic leukaemia. Br J Haematol 2001; 113:400-6. [PMID: 11380405 DOI: 10.1046/j.1365-2141.2001.02731.x] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
A large proportion of B-chronic lymphocytic leukaemia (B-CLL) cells express the anti-apoptotic protein Bcl-2. Basic fibroblast growth factor (bFGF) has been shown to upregulate the expression of Bcl-2 in B-CLL cell lines. Vascular endothelial growth factor (VEGF) has been shown to enhance the survival of endothelial cells by upregulating the expression of Bcl-2. In the present study, we measured serum and cellular levels of bFGF and VEGF in 85 patients with CLL using a commercial quantitative sandwich enzyme immunoassay technique. Levels of Bcl-2 were also assayed concomitantly using Western blot analysis. The mean serum level of bFGF was 53.4 pg/ml (range 0-589) and that of VEGF 459.2 pg/ml (range 33-1793). The mean cellular level of bFGF was 158.3 pg/2 x 105 cells (range 0.8-841) and VEGF, 42.4 pg/2 x 105 cells (range 0-244). A high correlation was found between serum and cellular bFGF levels (P < 0.001), but not between the corresponding VEGF levels. Twenty-nine of 69 patients (42%) evaluated for Bcl-2 level, expressed it. The Bcl-2 level was positively correlated with the serum bFGF level (P = 0.007). However, surprisingly there was a negative correlation between Bcl-2 expression and intracellular VEGF level (P = 0.003). A positive correlation was also found between serum bFGF and disease follow-up time and log white blood cell count. These findings indicate that in CLL there is a correlation between angiogenesis-related factors and apoptosis-related protein expression, and elevated bFGF levels may account for the elevated Bcl-2 levels.
Collapse
MESH Headings
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal/pharmacology
- Apoptosis
- Blotting, Western
- Cell Survival/drug effects
- Cells, Cultured
- Chi-Square Distribution
- Electrophoresis, Polyacrylamide Gel
- Endothelial Growth Factors/analysis
- Endothelial Growth Factors/blood
- Endothelial Growth Factors/immunology
- Enzyme-Linked Immunosorbent Assay
- Female
- Fibroblast Growth Factor 2/analysis
- Fibroblast Growth Factor 2/blood
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell/blood
- Leukemia, Lymphocytic, Chronic, B-Cell/immunology
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Leukocyte Count
- Lymphocytes/chemistry
- Lymphokines/analysis
- Lymphokines/blood
- Lymphokines/immunology
- Male
- Middle Aged
- Neovascularization, Pathologic
- Proto-Oncogene Proteins c-bcl-2/analysis
- Vascular Endothelial Growth Factor A
- Vascular Endothelial Growth Factors
Collapse
Affiliation(s)
- O Bairey
- Institute of Haematology and the Felsenstein Medical Research Centre, Rabin Medical Centre, Beilinson Campus, Petah Tikva, Israel.
| | | | | | | |
Collapse
|
14
|
Rabizadeh E, Bairey O, Aviram A, Ben-Dror I, Shaklai M, Zimra Y. Doxorubicin and a butyric acid derivative effectively reduce levels of BCL-2 protein in the cells of chronic lymphocytic leukemia patient. Eur J Haematol 2001; 66:263-71. [PMID: 11380606 DOI: 10.1034/j.1600-0609.2001.066004263.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
B-chronic lymphocytic leukemia (B-CLL) is a disease caused primarily by defects in the apoptosis mechanism. AN-9, a butyric acid (BA) derivative, is a potent differentiating and an anti-cancer drug that induces apoptosis in HL-60 cells. Herein we show the affect of AN-9, alone and in combination with doxorubicin, on cell cultures from B-CLL patients. Cells from 17 patients were cultured and tested for viability, apoptosis, bcl-2 and bax protein expression. Exposure of B-CLL cell cultures to AN-9 was accompanied by apoptosis and a marked viability loss (up to 46%, p=0.0017). AN-9 reduced up to 51% (p=0.0017) the levels of bcl-2 in 57% of the cultures that express bcl-2. The combination of low concentrations of AN-9 and doxorubicin more than additively enhanced apoptosis and reduced bcl-2 levels in B-CLL cultures which were resistant to AN-9. AN-9 enhanced bax expression up to 58%(p=0.008) in cultures from 53% of the patients, but had no effect on bax levels when combined with doxorubicin. In conclusion, AN-9 alone reduced bcl-2 and enhanced bax expression in cultures from B-CLL patients, and the reduction of bcl-2 levels in combination with doxorubicin was greater than additive. These results may be beneficial in possible future combination therapy with AN-9 in B-CLL.
Collapse
Affiliation(s)
- E Rabizadeh
- Institute of Hematology and Felsenstein Medical Research Center, Rabin Medical Center, Belinson Campus, Petach Tikva and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | | | | | | | | | | |
Collapse
|
15
|
Bairey O, Zimra Y, Kaganovsky E, Shaklai M, Okon E, Rabizadeh E. Microvessel density in chemosensitive and chemoresistant diffuse large B-cell lymphomas. Med Oncol 2000; 17:314-8. [PMID: 11114711 DOI: 10.1007/bf02782197] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2000] [Accepted: 06/05/2000] [Indexed: 12/22/2022]
Abstract
Preliminary reports involving a number of different kinds of tumors have indicated that microvessel quantification may be useful in predicting disease outcome. The aim of this study was to examine the relationship between microvessel density (MVD) as a parameter of tumor angiogenesis and the response to chemotherapy in diffuse large B-cell (DLBC) lymphomas. A total of 36 DLBC lymphoma patients were evaluated, 23 of them with a chemosensitive; responsive disease (median survival 8y) and 13 with a chemoresistant, refractory disease (median survival 8 months). Microvessel quantification was performed by immunohistochemical staining, using monoclonal antibodies against factor VIII related antigen (F8RA) and against platelet/endothelial cell adhesion molecule-CD31. We found that F8RA stained a significantly higher number of blood vessels (about 2.5 times more) than CD-31; 7 samples were not stained with CD-31 but were positive for F8RA. There was no significant difference between the density of microvessel staining of the two groups. In the chemosensitive DLBC lymphomas positive for F8RA, the mean number of microvessels stained was 54.5 +/- 36.1 per microscopic field (200x) examined (range 6-149) whereas in the chemoresistant group the corresponding mean number was 43.1 +/- 25.5 (range 11-94). F8RA appears to be more sensitive for staining DLBC lymphomas microvessels than CD-31. Our data demonstrate that there is no correlation between tumor MVD and response to chemotherapy in patients with DLBC lymphomas.
Collapse
Affiliation(s)
- O Bairey
- Institute of Hematology, and the Felsenstein Medical Research Center, Rabin Medical Center, Petah-Tikva, Israel.
| | | | | | | | | | | |
Collapse
|
16
|
Aviram A, Rabizadeh E, Zimra Y, Yeshoron M, Marmelstein M, Shaklai M, Bairey O. Expression of bcl-2 and bax in cells isolated from B-chronic lymphocytic leukemia patients at different stages of the disease. Eur J Haematol 2000; 64:80-4. [PMID: 10997327 DOI: 10.1034/j.1600-0609.2000.90042.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
B-Chronic lymphocytic leukemia (B-CLL) is an example of a human malignancy caused by alterations in the pathways of programmed cell death. In this disease the anti-apoptotic protein, bcl-2, is overexpressed and may lead to the prolonged survival of a malignant CLL clone. In the present study we examined the expression of bcl-2 and bax, which has an antagonistic role against the function of bcl-2, in cells from CLL patients at different stages of the disease, by immunoblot analysis. A direct association between the stage of the disease and the level of bcl-2 in the patients' cells was observed. At stages A and B, 33% and 29% of patients, respectively, expressed high levels of bcl-2, as opposed to 80% of patients at stage C (p= 0.019). Bax level was not significantly associated with the stage of the disease, although patients at stage C had higher levels of bax. In this study we found a trend of association between bcl-2 and bax levels. Analysis including all patients revealed that 65% of the patients who expressed high levels of bcl-2 had high levels of bax (p = 0.058). Of patients in stage C, 45% expressed high levels of both bcl-2 and bax while 50% and 42% of patients at stages A and B had low levels of both proteins.
Collapse
Affiliation(s)
- A Aviram
- Division of Haematology, Rabin Medical Center, Petach-Tikva, Israel.
| | | | | | | | | | | | | |
Collapse
|
17
|
Bairey O, Zimra Y, Shaklai M, Okon E, Rabizadeh E. Bcl-2, Bcl-X, Bax, and Bak expression in short- and long-lived patients with diffuse large B-cell lymphomas. Clin Cancer Res 1999; 5:2860-6. [PMID: 10537354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Abstract
Long-term cure is now possible for approximately 50% of all patients with aggressive non-Hodgkin's lymphoma (NHL). Apoptosis-related proteins play an important role in the chemosensitivity or chemoresistance of tumors. We examined the role of Bcl-2 family proteins in aggressive NHL. We retrospectively selected two groups of patients by clinical outcome: 24 patients with chemoresponsive disease and long survival (median, 88 months); and 20 patients with chemoresistant disease and short survival (median, 8 months). The expression of the apoptosis-regulating proteins, Bcl-2, Bcl-X, Bax, and Bak, in the initial biopsy samples was examined with immunohistochemical methods. Specimens containing >10% immunostained tumor cells were considered immunopositive. An inverse association was found between length of patient survival and expression of Bcl-2, Bcl-X, and Bax. Bcl-2 was expressed in 75% of short-lived patients but in only 42% of the long-lived ones (P = 0.026). Bcl-X expression was also higher in the short-lived patients (40% versus 12.5%; P = 0.036). Unexpectedly, Bax expression was strongly associated with short survival (60% versus 21%; P = 0.008). Several combinations of protein expression, i.e., Bcl-2 with Bax, Bcl-2 with Bcl-X, and Bcl-X with Bax, were different between the groups: a positive expression of these proteins was found in the short-lived patients. Furthermore, a strong association was found between the expression of Bcl-2 and Bcl-X, suggesting that Bcl-X potentiates rather than replaces the effect of Bcl-2 in NHL. In diffuse large B-cell NHL, Bcl-2, Bcl-X, and Bax expression alone or in combination is associated with chemoresistance and shortterm survival.
Collapse
Affiliation(s)
- O Bairey
- Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Israel
| | | | | | | | | |
Collapse
|
18
|
Aviram A, Blickstein D, Stark P, Luboshitz J, Bairey O, Prokocimer M, Shaklai M. Significance of BCR-ABL transcripts in bone marrow aspirates of Philadelphia-negative essential thrombocythemia patients. Leuk Lymphoma 1999; 33:77-82. [PMID: 10194123 DOI: 10.3109/10428199909093727] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Philadelphia-negative (Ph-neg) essential thrombocythemia (ET), polycythemia vera (PV) and idiopathic myelofibrosis (IMF) form a syndrome of related chronic myeloproliferative disorders (MPD) characterized by expansion of one or more of the hematopoietic progenitors. Based on our previous finding of BCR-ABL transcripts in bone marrow aspirates of 12/25 Ph-neg ET patients, we have expanded our study up to 40 patients. Here we describe the rational for performing this study and report 19 of 40 patients who have BCR-ABL transcripts in their BM, 11 of them carry b3a2 and 8 carry b2a2. The two groups, BCR-ABL positive and negative, were completely identical with regard to clinical characteristics and laboratory data. We also report preliminary results of our attempt to examine concordance or discordance of BCR-ABL expression in the peripheral blood and bone marrow of Ph-neg ET patients.
Collapse
Affiliation(s)
- A Aviram
- Division of Hematology, Rabin Medical Center, Beilinson Campus, Petach-Tikva, Israel
| | | | | | | | | | | | | |
Collapse
|
19
|
Luboshitz J, Bairey O, Blickstein D, Vaknin H, Okon E, Lahav J, Prokocimer M. Cutaneous necrosis as a terminal paraneoplastic thromboembolic event in a patient with non-Hodgkin's lymphoma. J Intern Med 1999; 245:301-5. [PMID: 10205593 DOI: 10.1046/j.1365-2796.1999.00475.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Thrombotic complications in non-Hodgkin's lymphoma often originate in the large veins. We describe a patient with refractory advanced high-grade lymphoma who presented with the rare complication of extensive cutaneous necrosis due to thrombosis of dermal vessels; there was also a recent new peak of monoclonal IgM-kappa protein. Direct immunofluorescence demonstrated immune deposits with complement in the dermal vessel wall. Based on these observations and on published data, we suggest that these complexes were the trigger for the thrombotic events and that the monoclonal IgM acted as xenoreactive antibodies, initiating a cascade of events. The first step of this cascade was activation of the complement and the membrane attack complex, which caused secretion of IL-1 alpha by endothelial cells, followed by overexpression of tissue factor on the surface of the dermal vessel wall endothelium. Dermal vessel thrombosis was the final event in this cascade.
Collapse
Affiliation(s)
- J Luboshitz
- Division of Hematology, Rabin Medical Center, Petah-Tikva, Israel
| | | | | | | | | | | | | |
Collapse
|
20
|
Blickstein D, Aviram A, Luboshitz J, Prokocimer M, Stark P, Bairey O, Sulkes J, Shaklai M. BCR-ABL transcripts in bone marrow aspirates of Philadelphia-negative essential thrombocytopenia patients: clinical presentation. Blood 1997; 90:2768-71. [PMID: 9326244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
One of the diagnostic criteria of essential thrombocythemia (ET) is the absence of the Philadelphia chromosome (Ph-neg). On the molecular level, Ph-neg ET patients may carry BCR-ABL transcript. The natural history of BCR-ABL positive Ph-neg ET patients is undetermined. We examined the BCR-ABL status by reverse transcriptase two-step nested polymerase chain reaction in bone marrow aspirates of 25 Ph-neg ET patients. We found 12 BCR-ABL positive and 13 BCR-ABL negative patients in the study group. The comparison showed that the two groups had similar clinical and laboratory characteristics, except for a significant increased patients' age and decreased polymorphonuclear cell count in the BCR-ABL positive group. During a median follow-up of 20 and 22.5 months for the BCR-ABL negative and positive groups, respectively, there was neither blastic transformation nor unrelated death in both groups. We conclude that it is important to look for BCR-ABL transcript in Ph-neg ET patients and to follow them closely to investigate the nature of this translocation in this group of patients.
Collapse
MESH Headings
- Adult
- Aged
- Blast Crisis
- Bone Marrow/pathology
- Cytogenetics/methods
- Diagnosis, Differential
- Disease Progression
- Female
- Follow-Up Studies
- Fusion Proteins, bcr-abl/genetics
- Humans
- In Situ Hybridization, Fluorescence
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology
- Male
- Middle Aged
- Philadelphia Chromosome
- Polymerase Chain Reaction
- RNA, Messenger/analysis
- RNA, Messenger/genetics
- Thrombocythemia, Essential/blood
- Thrombocythemia, Essential/diagnosis
- Thrombocythemia, Essential/genetics
- Thrombocythemia, Essential/pathology
Collapse
Affiliation(s)
- D Blickstein
- Division of Hematology, Rabin Medical Center, Beilinson Campus, Petah-Tikva, Israel
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Bairey O, Bishara J, Stahl B, Shaklai M. Severe tissue necrosis after cisplatin extravasation at low concentration: possible "immediate recall phenomenon". J Natl Cancer Inst 1997; 89:1233-4. [PMID: 9274921 DOI: 10.1093/jnci/89.16.1233] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
|
22
|
Bairey O, Gabbay U, Blickstein D, Stark P, Prokocimer M, Epstein O, Shaklai M, Lahav J. Levels of proteins C and S do not decline subsequent to first line chemotherapy in lymphoma patients. Hematol Oncol 1997; 15:121-7. [PMID: 9600111 DOI: 10.1002/(sici)1099-1069(199708)15:3<121::aid-hon606>3.0.co;2-d] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Thromboembolic complications and decrease in protein C and S have been observed in patients while receiving combination chemotherapy for breast cancer. We investigated whether initial cytotoxic treatment of non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD) is also associated with changes in these anticoagulant parameters. For this purpose 25 patients with intermediate to high grade NHL and seven with HD, undergoing primary treatment with cytotoxic drugs were evaluated at three time-points: pre-therapy, mid-therapy and post-therapy. In contrast to the breast cancer patients, no significant changes in protein C, protein S and antithrombin III levels were observed in the NHL patients during the various stages of therapy. However in HD patients, the mean protein C values had a tendency to be higher at mid-therapy compared to pre-therapy and protein S levels had a tendency to be higher at mid-therapy compared to post-therapy. In lymphoma patients receiving primary cytotoxic treatment we did not find changes in anticoagulant parameters that can explain a chemotherapy-induced hypercoagulable state, as has been reported in breast cancer patients.
Collapse
Affiliation(s)
- O Bairey
- Division of Hematology, Rabin Medical Center, Tel-Aviv, Israel
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Shaklai S, Bairey O, Blickstein D, Prokocimer M, Hadar H, Lahav M, Sulkes J, Shaklai M. Severe myelotoxicity of oral etoposide in heavily pretreated patients with non-Hodgkin's lymphoma or chronic lymphatic leukemia. Cancer 1996; 77:2313-7. [PMID: 8635101 DOI: 10.1002/(sici)1097-0142(19960601)77:11<2313::aid-cncr20>3.0.co;2-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
BACKGROUND Promising results have been reported for patients with non-Hodgkin's lymphoma (NHL) receiving chronic oral etoposide. Due to the small number of patients reported, information regarding side effects is limited, and therefore warrants further evaluation. METHODS Twenty eligible patients with NHL and chronic lymphatic leukemia (CLL), resistant to or relapsed after previous protocols of polychemotherapy were treated with oral etoposide at a dosage of 50 mg/m2/day for 21 days in a 28-day cycle. Response and toxicity were evaluated according to standard criteria. RESULTS Total response was noted in 13 patients, complete response in 2 patients, and partial response in 11 patients. Two patients had stable disease and five patients had progression of disease during treatment. Seventy-five percent of patients experienced neutropenia below 1500/microL. Half acquired infection and required hospitalization. Fifty-five percent required blood transfusions. All patients needed course shortening and dosage reduction. CONCLUSIONS Chronic daily administration of oral etoposide is effective in patients with NHL and CLL. In heavily pretreated patients, myelotoxicity is severe. Therefore, modification of the schedule plan is mandatory in this group of patients.
Collapse
Affiliation(s)
- S Shaklai
- Division of Hematology, Beilinson Medical Center, Petach Tikva, Israel
| | | | | | | | | | | | | | | |
Collapse
|
24
|
Bairey O, Huminer D, Sandbank J, Pitlik S. Bacterial lymphadenitis complicating chronic lymphatic leukemia. Isr J Med Sci 1994; 30:835-7. [PMID: 7982775] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Affiliation(s)
- O Bairey
- Division of Hematology, Beilinson Medical Center, Petah Tikva, Israel
| | | | | | | |
Collapse
|
25
|
Abstract
BACKGROUND Transposition of the ovaries is practiced in young women before possible radiation to the pelvic fields. In patients with carcinoma of the uterine cervix (Ca cervix), the ovaries are transposed laterally (LOT), whereas in patients with Hodgkin's disease (HD), they are usually transposed medially (MOT). Nevertheless, not all transposed ovaries are successfully protected. METHODS Computed tomography was performed in 16 patients (7 Ca cervix and 9 HD) after ovarian transposition. The location of all identified ovaries was depicted on diagrams of the respective radiation fields for evaluation of the efficacy of LOT or MOT in relocating the ovaries out of these fields. RESULTS All 13 ovaries transposed laterally were easily identified by CT, as compared with only 13 of 18 ovaries transposed medially (P = 0.2). Eleven of the 13 ovaries that underwent lateral transposition (6 of 7 patients) were located outside the radiation field. In contrast, only 3 of 13 identified ovaries in the medially transposed group were completely outside the radiation field (P = 0.005). Of the remainder, six were completely within the radiation field, and four were at least partially within the radiation field. CONCLUSIONS Although LOT achieves its purpose in patients with Ca cervix, the use of MOT in patients with HD should be revised to achieve better protection of the ovaries from the effects of radiation. The authors suggest that LOT is preferred over MOT also in patients with HD if radiation of the pelvic lymph nodes is planned.
Collapse
Affiliation(s)
- H Hadar
- Department of Radiology, Beilinson Medical Center, Petah Tiqva, Israel
| | | | | | | | | | | |
Collapse
|
26
|
Abstract
BACKGROUND The orbit is rarely a secondary site of lymphoma dissemination, and only few reports exist on the course and characteristics of involvement in these sites. METHODS The authors retrospectively reviewed the records of 187 consecutive patients with systemic non-Hodgkin's lymphoma (NHL) diagnosed and treated at Beilinson Medical Center between 1986 and 1992. RESULTS Ten patients (5.3% of those with NHL) had orbital or adnexal involvement or both. Histologically, six had intermediate-grade lymphoma, three had diffuse small cleaved cell lymphoma, and one had nodular small cleaved cell lymphoma. In all 10 patients, the lymphoma was widespread, and in 6, there were two or more other extranodal sites of involvement, mainly, bone marrow (six) and skin (three). The orbital involvement was found either at presentation or as late as 53 months after primary diagnosis. Various therapeutic approaches were chosen, from local orbital irradiation to different mild to aggressive chemotherapeutic protocols. Complete regression of the orbital or adnexal involvement or both was observed in 9 of 10 patients, but in 6 the systemic disease either persisted or recurred at other sites. CONCLUSIONS Orbital or adnexal involvement or both by NHL may appear at any time during the course of the disease. It responds well to either chemotherapy or radiation therapy with prolonged local remission. The results of this study strongly suggest that every patient with NHL in whom any periorbital or orbital mass, ptosis, proptosis or lid edema develops should be suspected of having orbital lymphoma involvement until proven otherwise.
Collapse
Affiliation(s)
- O Bairey
- Division of Hematology, Beilinson Medical Center, Petah Tiqva, Israel
| | | | | | | | | |
Collapse
|
27
|
Bairey O, Inbal A. [Desmopressing (DDAVP) treatment in patients with bleeding tendency]. Harefuah 1993; 125:105-107. [PMID: 8225075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
|
28
|
Bairey O, Huminer D, Blickstein D, Sandbank Y, Shaklai M. [Relapse of multiple myeloma in extramedullary sites]. Harefuah 1993; 124:539-41, 600. [PMID: 8340001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Multiple myeloma was diagnosed in a 69-year-old man with pathological hip fracture, who had increased plasma cells in the bone marrow, osteolytic lesions in bones, low level of monoclonal protein (IgAK) in serum and urine, and anemia, hypercalcemia and renal insufficiency. He was treated for 1 year with chemotherapy with good results. 6 months after cessation of treatment the disease relapsed with multiple extramedullary plasmacytomas in skin and subcutaneous areas, right eyebrow, right knee, sternum and right axilla, but repeated bone marrow examinations were without evidence of disease activity. Chemotherapy was resumed but the patient died 1.5 years after the relapse with severe jaundice due to multiple liver plasmacytomas and pelvic masses.
Collapse
Affiliation(s)
- O Bairey
- Dept. of Medicine C, Beilinson Medical Center, Petah Tikva
| | | | | | | | | |
Collapse
|
29
|
Bairey O. [Glucocorticoid-induced osteoporosis: pathogenesis and management]. Harefuah 1992; 123:479-83. [PMID: 1487208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
30
|
Kremer I, Bairey O, Shaklai M. [Lymphoproliferative disorders of the orbit: immunohistopathogenic approach]. Harefuah 1992; 122:251-3. [PMID: 1563690] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
31
|
Abstract
While haemarthrosis is a common finding in severe factor VIII or IX deficiency, it is unusual in mild coagulation factor deficiencies. We describe three patients with mild factor IX, X or XI deficiency who presented with spontaneous haemarthrosis. All underwent joint puncture with subsequent worsening of the haemarthrosis in the affected joint. This report indicates that: (i) even mild coagulation factor deficiency may be associated with haemarthrosis; (ii) patients with suspected haemarthrosis should undergo routine screening coagulation tests before joint puncture; and (iii) any abnormalities in the screening tests indicate a need for further evaluation of the coagulation status. In such cases puncture of the joint should be deferred and specific therapy started immediately.
Collapse
Affiliation(s)
- O Bairey
- Division of Hematology, Beilinson Medical Center, Petah Tiqva, Israel
| | | | | |
Collapse
|
32
|
Friedensohn A, Faibel HE, Bairey O, Goldbourt U, Schlesinger Z. Malignant arrhythmias in relation to values of serum potassium in patients with acute myocardial infarction. Int J Cardiol 1991; 32:331-8. [PMID: 1686433 DOI: 10.1016/0167-5273(91)90295-z] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The relationship between levels of potassium in the serum and the development of malignant arrhythmias was examined in a retrospective study involving 1011 patients presenting with acute myocardial infarction. Thirteen percent of the overall patients studied had significant hypokalemia (k less than 3.5 mmol/liter). The average initial level of potassium in patients who developed malignant arrhythmias was (4.10 mmol/liter) significantly lower (P less than 0.01) than those patients who did not develop such arrhythmias (4.19 mmol/liter). To determine whether the level of potassium was, in itself, the primary cause of malignant arrhythmias following myocardial infarction, a subgroup analysis of factors influencing these levels was performed. It was determined that diabetics have a higher level of potassium than nondiabetics (4.2 mmol/liter versus 4.11 mmol/liter - P = 0.01) and a lower incidence of malignant arrhythmias (50.5% versus 63.5% - P = 0.002). No correlation was found between treatment with either digitalis or diuretics and malignant arrhythmias. Size and location of infarcted areas was found to have a direct relationship with development of arrhythmias. Size and location of infarctions, however, were not found to be related to levels of potassium in the serum. Our findings support and clarify earlier suggestions establishing the levels of potassium in the serum as an important causative factor, together with size and location of infarctions, in the development of malignant arrhythmias.
Collapse
Affiliation(s)
- A Friedensohn
- Heart Institute, Assaf Harofeh Medical Center, Zerifin, Israel
| | | | | | | | | |
Collapse
|
33
|
Bairey O, Kremer I, Shaklai M. [Intraocular, orbital and ocular adnexal lymphoid neoplasms]. Harefuah 1991; 120:408-10. [PMID: 1879795] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
34
|
Prokocimer M, Modan M, Rusoshansky S, Bairey O, Shaklai M. ProMACE-CytaBOM: combination chemotherapy for diffuse large cell lymphoma. Anticancer Res 1989; 9:1233-5. [PMID: 2479327] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
ProMACE CytaBOM, a polychemotherapy regimen consisting of cyclophosphamide, doxorubicin, etoposide cytozar, bleomycin, vincristine, methotrexate and prednisone was administered on an outpatient basis to six consecutive patients with diffuse large cell lymphoma. All achieved a complete remission (CR). Two have relapsed. Actuarial analysis predicts 66.7% survival and 62.5% probability of remaining in remission at 40 months post diagnosis. The side effects of ProMACE CytoBOM were tolerable and included mainly vincristine induced peripheral neuropathy, infections and mucositis. Our results are consistent with the SWOG results, reported only recently, using the same combination chemotherapy regimen in patient with intermediate and high-grade non-Hodgkin's lymphomas. We conclude that ProMACE CytaBOM represents a highly effective and easy-to-administer regimen in patients with large cell lymphoma.
Collapse
Affiliation(s)
- M Prokocimer
- Hematology Division, Beilinson Medical Center, Petah Tiqva, Israel
| | | | | | | | | |
Collapse
|